Edwards Lifesciences delivered strong Q3 2025 results with 12.6% sales growth, driven by a comprehensive portfolio in structural heart therapies, prompting an upward revision of full-year guidance for sales and EPS.

• Q3 revenues reached $1.55 billion, exceeding expectations and reinforcing the company's growth strategy.
• Full-year sales growth guidance revised to the upper end of 9-10% range, with EPS guidance raised to $2.56–$2.62.
• Strong performance from innovative TAVR therapies, particularly SAPIEN, enhances long-term adoption and market competitiveness.
• Positive clinical data presented at TCT further supports the efficacy and durability of the TAVR products and positions Edwards for sustained growth in the TMTT market, projected to reach $2 billion by 2030.
• The company’s diverse portfolio now addresses multiple valve disease areas, ensuring comprehensive treatment options for patients and solidifying its leadership in the field.